Business
Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India
First authorization of Novavax' COVID-19 vaccine in adolescent population receivedCovovax™ (SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein
About this update from Novavax, Inc.
[{"type":"text","content":"First authorization of Novavax' COVID-19 vaccine in adolescent population receivedCovovax™ (SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine) is the first protein-based COVID-19 vaccine authorized for adolescents ≥12 to","length":356,"tagName":"div"}]